Over the last 20 years, the efforts to develop new therapies for Parkinson's disease (PD) have focused not only on the improvement of symptomatic therapy for motor and non-motor symptoms but also on the discovering of the potential causes of PD, in order to develop disease-modifying treatments. The emerging role of dysregulation of the Wnt/β-catenin signaling in the onset and progression of PD, as well as of other neurodegenerative diseases (NDs), renders the targeting of this signaling an attractive therapeutic opportunity for curing this brain disorder. The natriuretic peptides (NPs) atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and C-type natriuretic peptide (CNP), are cardiac and vascular-derived hormones also widely expressed in mammalian CNS, where they seem to participate in numerous brain functions including neural development/differentiation and neuroprotection. We recently demonstrated that ANP affects the Wnt/β-catenin pathway possibly through a Frizzled receptor-mediated mechanism and that it acts as a neuroprotective agent in in vitro models of PD by upregulating this signaling. Here we provide further evidence supporting the therapeutic potential of this class of natriuretic hormones. Specifically, we demonstrate that all the three natriuretic peptides are neuroprotective for SHSY5Y cells and primary cultures of DA neurons from mouse brain, subjected to neurotoxin insult with 6-hydroxydopamine (6-OHDA) for mimicking the neurodegeneration of PD, and these effects are associated with the activation of the Wnt/β-catenin pathway. Moreover, ANP, BNP, CNP are able to improve and accelerate the dopaminergic differentiation and maturation of hiPSCs-derived neural population obtained from two differed healthy donors, concomitantly affecting the canonical Wnt signaling. Our results support the relevance of exogenous ANP, BNP, and CNP as attractive molecules for both neuroprotection and neurorepair in PD, and more in general, in NDs for which aberrant Wnt signaling seems to be the leading pathogenetic mechanism.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8560781PMC
http://dx.doi.org/10.1038/s41420-021-00723-6DOI Listing

Publication Analysis

Top Keywords

natriuretic peptides
12
natriuretic peptide
12
peptides neuroprotective
8
vitro models
8
dopaminergic differentiation
8
wnt/β-catenin signaling
8
wnt/β-catenin pathway
8
anp bnp
8
bnp cnp
8
wnt signaling
8

Similar Publications

Background: N-terminal brain natriuretic peptide (NTproBNP) is a marker of cardiac health and a strong predictor of mortality, incident cardiovascular disease (CVD), and sudden cardiac death in community populations. A link between the menopause transition (MT), sex hormones, and NTproBNP has been suggested, though, no studies have formally examined how NTproBNP changes over the MT. In addition of being a marker of cardiac health, studies suggest NTproBNP to be related to cognitive performance, yet those studies have not considered the MT.

View Article and Find Full Text PDF

Background: Subclinical cardiovascular disease (CVD), assessed by high-sensitivity cardiac troponin T (hs-cTnT) and N-terminal pro-B-type natriuretic peptide (NT-proBNP), is linked to cognitive decline, but the associations in hypertensive adults and the underlying brain pathologies remain unclear. It is also undetermined whether an intensive blood pressure treatment compared to a standard treatment may slow down cognitive decline associated with subclinical CVD.

Method: We conducted a post hoc analysis of the Systolic Blood Pressure Intervention Trial, where older adults with hypertension were randomized to an intensive treatment (systolic blood pressure (SBP) target of < 120 mm Hg) or standard treatment (< 140 mm Hg).

View Article and Find Full Text PDF

Biomarkers.

Alzheimers Dement

December 2024

TOSOH Corporation, Ayase-shi, Kanagawa, Japan.

Background: Neurodegenerative diseases, such as Alzheimer's disease(AD), have become more prevalent in aging societies. Therefore, it is important to develop a blood-based measurement system to diagnose early-stage AD. However, such AD-related biomarkers in blood exist at extremely low levels and are difficult to detect precisely and reproducibly.

View Article and Find Full Text PDF

Aim: To identify predictors and construct a model for predicting left ventricular (LV) ejection fraction (EF) in patients with ST-segment elevation myocardial infarction (STEMI).

Material And Methods: This was a prospective registry study of patients with STEMI admitted within the first 24 hours of the disease onset. Patients were evaluated and treated according to the current clinical guidelines.

View Article and Find Full Text PDF

Background: Unexplained exertional dyspnoea without significant elevation of natriuretic peptides is common. One of the causes might be early heart failure with preserved ejection fraction (HFpEF).

Aims: This study aimed to characterize patients with exertional dyspnoea and normal/near-to-normal N-terminal pro-brain natriuretic peptide (NT-proBNP) levels with regard to early stages of HFpEF and non-cardiac causes.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!